Literature DB >> 7534858

HIV-1 RNA serum-load and resistant viral genotypes during early zidovudine therapy.

C Loveday1, S Kaye, M Tenant-Flowers, M Semple, U Ayliffe, I V Weller, R S Tedder.   

Abstract

The response of HIV-1 to initial zidovudine (ZDV) treatment was assessed in 11 patients with severe HIV disease. We quantified serum HIV-1 concentrations and mutations associated with ZDV resistance by culture-independent methods. There was a prompt fall in serum HIV-1 RNA within 1-2 days of treatment with maximum suppression by seven days, which was paralleled by changes in serum p24 antigen (p24 Ag). Serum RNA started to return to pretreatment levels within weeks. The HIV reverse transcriptase (RT) gene in most patients developed mutations associated with drug resistance within months and as early as 25 days on therapy in one patient. The codon changes were not sufficient to explain the early return of serum HIV-1 RNA levels and their patterns continued to evolve after patients stopped taking ZDV. The significance of these findings is discussed in relation to the limited long-term efficacy of ZDV. The dynamic time course of viral load and RT responses to ZDV is of particular importance in short-term interventions such as pregnancy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534858     DOI: 10.1016/s0140-6736(95)92963-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  22 in total

Review 1.  Measuring sexual behaviour: methodological challenges in survey research.

Authors:  K A Fenton; A M Johnson; S McManus; B Erens
Journal:  Sex Transm Infect       Date:  2001-04       Impact factor: 3.519

2.  Antiretroviral Drug Resistance in HIV-1.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

3.  Short-term effect of zidovudine on plasma and genital human immunodeficiency virus type 1 and viral turnover in these compartments.

Authors:  Dorothy Mbori-Ngacha; Barbra A Richardson; Julie Overbaugh; Dana DeVange Panteleeff; Ruth Nduati; Matt Steele; Grace John-Stewart
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

4.  Use of viral resistance patterns to antiretroviral drugs in optimising selection of drug combinations and sequences.

Authors:  G J Moyle
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

5.  Proton MRS and quantitative MRI assessment of the short term neurological response to antiretroviral therapy in AIDS.

Authors:  I D Wilkinson; S Lunn; K A Miszkiel; R F Miller; M N Paley; I Williams; R J Chinn; M A Hall-Craggs; S P Newman; B E Kendall; M J Harrison
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

6.  Comparison of culture- and non-culture-based methods for quantification of viral load and resistance to antiretroviral drugs in patients given zidovudine monotherapy.

Authors:  R S Tedder; S Kaye; C Loveday; I V Weller; D Jeffries; J Norman; J Weber; M Bourelly; R Foxall; A Babiker; J H Darbyshire
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

7.  Antibiotic resistance: an increasing problem?. It always has been, but there are things we can do.

Authors:  C A Hart
Journal:  BMJ       Date:  1998-04-25

8.  Virus dynamics and drug therapy.

Authors:  S Bonhoeffer; R M May; G M Shaw; M A Nowak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-24       Impact factor: 11.205

9.  Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine.

Authors:  M D de Jong; J Veenstra; N I Stilianakis; R Schuurman; J M Lange; R J de Boer; C A Boucher
Journal:  Proc Natl Acad Sci U S A       Date:  1996-05-28       Impact factor: 11.205

10.  Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication.

Authors:  A M Caliendo; A Savara; D An; K DeVore; J C Kaplan; R T D'Aquila
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.